Latham & Watkins represented Merus N.V. in the transaction. Merus N.V. (Merus), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), has announced…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Ambrogio Visconti
…
This content is for Standard 1 Year members only. LoginJoin Now